MS vs NMR
Morgan Stanley and Nomura Holdings, Inc., both Financial Services
Morgan Stanley is the larger company at $352B against $26B. Over the past year MS returned +54% against +45% for NMR. Ryufin's sector-relative Smart Score puts NMR ahead, 8/10 against 6/10.
| Figure | MS | NMR |
|---|---|---|
| Last close | $214 | $10.05 |
| Market cap | $352B | $26B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.3 | n/a |
| Dividend yield | 1.8% | n/a |
| 1-year return | +54% | +45% |
| 5-year return | +160% | +123% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Morgan Stanley
Revenue of $21B in Q2 2026, net income $5.6B.
Nomura Holdings, Inc.
Revenue of $2.4T in H2 2026, net income $165B.
Open these two in the interactive comparison to add more names, change the period or read the correlation.